Team
Miro Venturi
More about Miro
Miro Venturi is a seasoned pharmaceutical and diagnostics executive with over 25 years of industry experience. His career spans several senior roles across large and mid sized healthcare organizations.
Miro is known for his significant contributions to the field of precisione medicine and his leadership of teams and organizations who thrive and grow, lead with strong business acumen, empathy and warm, focused charisma.
Miro has been SVP of Precision Medicine and Diagnostics Biomarkers at Roche, CBO at Foundation Medicine, CEO at Sintetica, and is an appointed Board Director in several precision medicine and diagnostics companies wit global footprint. He is also an advisor to venture funds and an Operating Partner at ARCHIMED, a 10 Bio Euro growth accelerator fund.
Katharina Venturi
More about Katharina
Katharina is a drug development expert with 20 years of expertise in pharmaceutical industry drug development, ranging from drug discovery to clinical development across a broad range of therapeutic indications including oncology, immunology, as well as cardiovascular and rare diseases.
Holding a PhD in Infection Biology/Immunology from Karolinska Institute, Stockholm, Sweden, Katharina began her pharmaceutical career at Roche as a project leader in Oncology, where she supported the development of several large molecule early-portfolio oncology products. She then moved to Actelion (now Idorsia) to drive the development of pre-clinical and clinical small molecule assets in several disease indications including respiratory conditions, autoimmune disorder and cardiovascular conditions.
Since 2020, Katharina followed her passion for driving cutting edge science to bring patients benefit by supporting biotech companies. As a hands-on consultant or fractional management support, she provides broad drug development expertise (preclinical, regulatory/ IND-enabling programs, translational/biomarker strategy, clinical POC and long-term development). She has an integrative working style and brings teams together to thrive and perform at their best.
Since the foundation of DIAMANTE she leads the Biopharma vertical and primarily works with Biotech customers in the field of oncology, immunology, and rare diseases.
Priyanka Dutta-Passecker
More about Priyanka
Priyanka is a biotechnology leader and entrepreneur with 18+ years of experience turning cell, gene, and regenerative medicine innovations into scalable, commercially viable products.
Holding a PhD in Neuroscience from Trinity College Dublin, Ireland and dual Executive MBAs from WU Executive Academia, Austria and the Carlson School of Management, USA, she blends deep scientific expertise with strategic and commercial leadership.
Priyanka’s track record spans CEO and Managing Director roles across Europe—including Co‑founder & CEO of Healiva SA and Managing Director & CEO of Neurolentech—along with global leadership positions at Novartis, UCB, Bioseutica, and Axol Bioscience.
She also serves on boards and advisor for emerging Swiss and Austrian startups, including Juvion and TiliaHealth. She has scaled companies, secured international partnerships, unlocked funding, and led multimillion‑euro commercialization efforts across Asia, Europe, and the US.
Recognized among Ernst & Young’s Entrepreneurial Winning Women (EMEIA), Priyanka also co‑founded the WU EA Female Leaders Network, one of Central Europe’s largest platforms for advancing women in leadership and advises the India–Austria Startup Bridge to foster cross‑border innovation.
René Dumay-Roscher
More about René
René is a drug development executive with over 25 years of experience in drug discovery, pre-clinical and clinical drug development, medical devices, and life-cycle management across cardiovascular, respiratory, oncology, metabolic, CNS and rare genetic diseases.
After his specialization in clinical pharmacokinetics at Boehringer Ingelheim, he has successfully led multiple global cross-functional development programs from preclinical discovery through Phase 3 and regulatory approval at ALTANA Pharma (now Takeda), Actelion (now J&J) and Idorsia, including multiple IND filings and the submission and approval of three NDAs/MAAs in US, EU, Japan, and South Korea.
His expertise spans preclinical development, clinical development & biomarker strategy, orphan disease development, regulatory interactions, CMC, and commercialization strategies. He has significant experience in managing alliances, licensing opportunities, and cross-industry collaborations.
In his current function at DIAMANTE Biopharma, he provides strategic guidance and hands-on leadership for emerging companies.
Stephan Jäger
More about Stephan
Stephan has over 25 years of experience in diagnostics and pharmaceutical development, with a focus on diagnostic biomarkers, technologies, and precision medicine across therapeutic areas including oncology, neuroscience, cardiovascular medicine, inflammation, rare diseases, and infectious diseases.
Stephan holds a PhD in Biology from the Eberhard-Karls-Universität Tübingen.
He spent most of his career at Roche Diagnostics, progressing from in-vitro diagnostic assay development and oncology biomarker assessment to PHC Partnering Director. In this role, he acted as liaison between Roche Pharma and Diagnostics, contributing to biomarker and precision medicine strategies, companion diagnostic co-development, and the evaluation of biomarkers, technologies, and companies.
At DIAMANTE, he enriches the Diagnostics vertical and works with clients at the interface of biomarker science, diagnostics, and precision medicine.
